Compare H2O America (HTO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Viatris Inc — how do they compare? H2O America trades at $63.83 (market cap $2.70B), while Viatris Inc trades at $17.38 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 7.3× H2O America's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| HTO | VTRS | |
|---|---|---|
Market Cap | $2.70B | $19.79B |
Sector | Technology | Health |
52-Week High | $65.43 | $17.39 |
52-Week Low | $44.44 | $8.74 |
Enterprise Value | $4.42B | $32.00B |
Dividend Yield | 2.73% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $64.52, down 1.39% today, with strong technical indicators showing a bullish trend. The company maintains solid fundamentals with 12.87% net income margin and consistent earnings beats in recent quarters. Recent news highlights upcoming Q2 2026 earnings report on July 27, 2026, and institutional buying activity. Technical analysis shows support at $62-$64 with resistance at $65-$66 levels.
HTO presents a balanced investment case with 80% analyst buy ratings and a $63.50 consensus target. The water utility's stable revenue streams and dividend yield provide defensive characteristics, though valuation multiples appear full and RSI levels suggest near-term overbought conditions. Execution on $2.7 billion capex plan remains key for growth.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
